FATE

Fate Therapeutics Inc.

Price

$2.65

return (12m)

132.46%

p/e

-2.44

p/bv

2.01

DIVIDEND YIELD

0.00%

FATE price

Fate Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment FATE

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-5.53%

3 months

26.19%

1 year

132.46%

2 years

-27.00%

5 years

-96.05%

10 years

-8.30%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals FATE

Valuation

P/E

-2.44

Sector -4.38

Industry -4.38

P/BV

2.01

Sector 2.02

Industry 2.02

P/Revenue (PSR)

47.43

Sector -4.40

Industry -4.40

EV/EBITDA

-5.43

Sector -263.09

Industry -263.09

EV/EBIT

-4.95

Sector -702.90

Industry -702.90

P/EBITDA

-2.53

Sector -4.39

Industry -4.39

P/EBIT

-2.30

Sector -4.73

Industry -4.73

P/Total Assets

1.18

Sector 1.49

Industry 1.49

P/Net Current Assets

6.00

Sector -11.70

Industry -11.70

P/Working Capital

2.46

Sector -3.19

Industry -3.19

EPS

-1.05

Sector -2.14

Industry -2.14

BVPS

1.28

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-1,362.98%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-1,496.63%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.01

Sector 0.03

Industry 0.03

Profitability

ROE

-82.11%

Sector -65.14%

Industry -65.14%

ROA

-48.44%

Sector -65.53%

Industry -65.53%

ROIC

-105.66%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

4.85

Sector 2.90

Industry 2.90

Net Debt / EBITDA

5.42

Sector -6.07

Industry -6.07

Net Debt / EBIT

4.94

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.00

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.59

Sector 0.41

Industry 0.41

Liabilities/Assets

0.41

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-34.98%

Sector -

Industry -

5Y Earnings CAGR

-9.90%

Sector -

Industry -

Fundamentals FATE

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
FATE Fate Therapeutics Inc.	$2.65	120.83%	0.00%	-2.44	2.01	-82.11%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

FATE Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Fate Therapeutics

Fate Therapeutics Inc.

Average Investor10 user rating

4.0 (3 people)

United States

19 years

Founded: 2007

2013

Time since IPO - 13 years

178

Employees

Fate Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $307.80 million, with shareholders equity totaling $153.44 million.

The company employs approximately 178 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Fate Therapeutics Inc. reported $6.49 million in revenue, generating net income of $-125.99 million.

Key financial metrics include a P/E ratio of -2.44, a price-to-book (P/B) ratio of 2.01, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker FATE.

Market cap

$307.80 million

Net worth

$153.44 million

$153,440,000.00

Assets

$260.10 million

$260,100,000.00

Total Shares Outstanding

120.00 million

120,000,000

Average Daily Trading Volume

$3.34 million

$3,339,688.12

Sector

Health Care

Industry

Biotechnology

FATE

FATE revenue and profits

Financial Results FATE

DRAG THE FRAME TO SEE MORE DATA

FATE cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Fate Therapeutics (FATE) today?

A cotação de Fate Therapeutics (FATE) hoje está em US$ 2.65, com uma variação de 132.46% em relação ao último ano. A cotação de Fate Therapeutics (FATE) iniciou o ano negociando na casa dos US$ 0.98 e hoje está em US$ 2.65. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Fate Therapeutics (FATE) e dados de ações do Ibovespa e mercados internacionais.

Quando Fate Therapeutics (FATE) paga dividendos?

Fate Therapeutics (FATE) não distribuiu dividendos no último ano.

Is Fate Therapeutics (FATE) a good investment?

Atualmente, Fate Therapeutics (FATE) está cotada a US$ 2.65, com um P/L de -2.44, representando um desvio de -202% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 132.46 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 132.46%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Fate Therapeutics (FATE) stock?

Investir em ações de Fate Therapeutics (FATE) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Fate Therapeutics (FATE) yield today?

A rentabilidade de Fate Therapeutics (FATE) foi de -5.53% no último mês, 132.46% no último ano e -96.05% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Fate Therapeutics (FATE) hoje, o investimento total seria de US$ 265.00, com base na cotação atual de US$ 2.65.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 616.02
Em 5 anos: US$ 10.47
Em 10 anos: US$ 243.01

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

FATE

Fate Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment FATE

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING FATE WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Fate Therapeutics

Fate Therapeutics Inc.

United States

19 years

2013

178

PROFIT X PRICE FATE

Financial Results FATE

FATE cash flow

Asset, Revenue and Profit Growth - FATE

FATE balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions